Sarepta Therapeutics annual free cash flow per share
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Sarepta Therapeutics Free Cash Flow Per Share Growth & History (SRPT)
Sarepta Therapeutics's free cash flow per share was -$3.07 for fiscal 2025.
View full Sarepta Therapeutics company overviewSarepta Therapeutics annual free cash flow per share history
| Fiscal year | Period ended | Free cash flow per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | -$3.07 | $0.53 | — |
| 2024 | 2024-12-31 | -$3.60 | $2.64 | — |
| 2023 | 2023-12-31 | -$6.25 | -$2.18 | — |
| 2022 | 2022-12-31 | -$4.07 | $1.86 | — |
| 2021 | 2021-12-31 | -$5.93 | -$6.25 | — |
| 2020 | 2020-12-31 | $0.32 | $7.33 | — |
| 2019 | 2019-12-31 | -$7.01 | -$0.22 | — |
| 2018 | 2018-12-31 | -$6.79 | -$2.64 | — |
| 2017 | 2017-12-31 | -$4.15 | $1.01 | — |
| 2016 | 2016-12-31 | -$5.16 | -$1.54 | — |
| 2015 | 2015-12-31 | -$3.61 | $0.23 | — |
| 2014 | 2014-12-31 | -$3.85 | -$1.87 | — |
| 2013 | 2013-12-31 | -$1.98 | -$0.72 | — |
| 2012 | 2012-12-31 | -$1.26 | -$0.11 | — |
| 2011 | 2011-12-31 | -$1.15 | -$0.29 | — |
| 2010 | 2010-12-31 | -$0.87 | -$0.24 | — |
| 2009 | 2009-12-31 | -$0.63 | — | — |
Sarepta Therapeutics quarterly free cash flow per share
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.86 | -$0.48 | −20.42% |
| Q1 2026 | 2026-03-31 | -$1.95 | $4.49 | — |
| Q4 2025 | 2025-12-31 | $1.22 | — | — |
| Q3 2025 | 2025-09-30 | -$0.37 | $0.76 | — |
| Q2 2025 | 2025-06-30 | $2.34 | $2.49 | — |
| Q1 2025 | 2025-03-31 | -$6.44 | -$3.52 | — |
| Q3 2024 | 2024-09-30 | -$1.13 | $0.49 | — |
| Q2 2024 | 2024-06-30 | -$0.15 | $1.43 | — |
| Q1 2024 | 2024-03-31 | -$2.92 | -$0.44 | — |
| Q3 2023 | 2023-09-30 | -$1.62 | -$0.79 | — |
| Q2 2023 | 2023-06-30 | -$1.58 | -$0.71 | — |
| Q1 2023 | 2023-03-31 | -$2.48 | -$1.26 | — |
| Q3 2022 | 2022-09-30 | -$0.84 | $0.84 | — |
| Q2 2022 | 2022-06-30 | -$0.87 | $0.58 | — |
| Q1 2022 | 2022-03-31 | -$1.22 | $1.31 | — |
| Q3 2021 | 2021-09-30 | -$1.67 | $1.68 | — |
| Q2 2021 | 2021-06-30 | -$1.44 | $0.18 | — |
| Q1 2021 | 2021-03-31 | -$2.54 | -$10.63 | — |
| Q4 2020 | 2020-12-31 | -$2.57 | -$0.15 | — |
| Q3 2020 | 2020-09-30 | -$3.36 | -$2.32 | — |
| Q2 2020 | 2020-06-30 | -$1.63 | -$0.33 | — |
| Q1 2020 | 2020-03-31 | $8.09 | $10.36 | — |
| Q4 2019 | 2019-12-31 | -$2.43 | -$0.35 | — |
| Q3 2019 | 2019-09-30 | -$1.04 | $0.98 | — |
| Q2 2019 | 2019-06-30 | -$1.29 | $0.63 | — |
| Q1 2019 | 2019-03-31 | -$2.27 | -$1.53 | — |
| Q4 2018 | 2018-12-31 | -$2.08 | -$1.53 | — |
| Q3 2018 | 2018-09-30 | -$2.01 | -$1.06 | — |
| Q2 2018 | 2018-06-30 | -$1.92 | -$0.32 | — |
| Q1 2018 | 2018-03-31 | -$0.74 | $0.40 | — |
| Q4 2017 | 2017-12-31 | -$0.54 | $1.00 | — |
| Q3 2017 | 2017-09-30 | -$0.95 | $0.32 | — |
| Q2 2017 | 2017-06-30 | -$1.60 | -$0.65 | — |
| Q1 2017 | 2017-03-31 | -$1.14 | $0.22 | — |
| Q4 2016 | 2016-12-31 | -$1.54 | -$0.82 | — |
| Q3 2016 | 2016-09-30 | -$1.27 | -$0.13 | — |
| Q2 2016 | 2016-06-30 | -$0.95 | -$0.24 | — |
| Q1 2016 | 2016-03-31 | -$1.35 | -$0.29 | — |
| Q4 2015 | 2015-12-31 | -$0.72 | -$0.03 | — |
| Q3 2015 | 2015-09-30 | -$1.14 | $0.02 | — |
| Q2 2015 | 2015-06-30 | -$0.71 | $0.40 | — |
| Q1 2015 | 2015-03-31 | -$1.06 | -$0.17 | — |
| Q4 2014 | 2014-12-31 | -$0.69 | -$0.20 | — |
| Q3 2014 | 2014-09-30 | -$1.16 | -$0.54 | — |
| Q2 2014 | 2014-06-30 | -$1.10 | -$0.72 | — |
| Q1 2014 | 2014-03-31 | -$0.89 | -$0.42 | — |
| Q4 2013 | 2013-12-31 | -$0.49 | -$0.22 | — |
| Q3 2013 | 2013-09-30 | -$0.62 | -$0.28 | — |
| Q2 2013 | 2013-06-30 | -$0.39 | -$0.13 | — |
| Q1 2013 | 2013-03-31 | -$0.47 | -$0.07 | — |
| Q4 2012 | 2012-12-31 | -$0.27 | -$0.01 | — |
| Q3 2012 | 2012-09-30 | -$0.34 | $0.00 | — |
| Q2 2012 | 2012-06-30 | -$0.26 | -$0.22 | — |
| Q1 2012 | 2012-03-31 | -$0.40 | $0.15 | — |
| Q4 2011 | 2011-12-31 | -$0.26 | — | — |
| Q3 2011 | 2011-09-30 | -$0.35 | — | — |
| Q2 2011 | 2011-06-30 | -$0.04 | — | — |
| Q1 2011 | 2011-03-31 | -$0.55 | — | — |
Sarepta Therapeutics free cash flow per share trends
Over the last five fiscal years, Sarepta Therapeutics's free cash flow per share decreased from $0.32 to -$3.07, a change of -$3.39. The latest reported quarter, Q2 2026, shows $1.86.
About the metric
What free cash flow per share means
Free cash flow per share estimates the free cash flow generated for each weighted-average common share. It combines operating cash generation, capital spending, and the share base into a per-share measure that can be compared over time.
Calculation and source
How free cash flow per share is calculated
TickerStat calculates free cash flow as operating cash flow minus capital expenditures, then divides it by basic weighted-average shares for the aligned fiscal period. Reliable filing-derived share counts are used when a filer omits the direct weighted-average-share fact. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sarepta Therapeutics source filings ↗Community posts
Novartis’ DM1 trial misses its primary endpoint
Novartis’ ($NVS) del-desiran failed to show a statistically significant improvement on the primary endpoint in the Phase III HARBOR trial for myotonic dystrophy type 1. The company will continue analysing the data and discuss next steps wit ...